Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aprecia

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

- PMLiVE

Health on instalment

Can US-style financial engineering underwrite ultra-expensive gene therapies?

- PMLiVE

Seattle Genetics claims key US approval for Adcetris

Becomes the first new treatment for advanced Hl in more than 40 years

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

- PMLiVE

Porterhouse Medical expands into the US

UK med comms group opens new subsidiary in Philadelphia

Nobody knew healthcare was so complicated

short term and long term solutions

- PMLiVE

FDA panel backs Indivior’s drug to fight opioid addiction

The former RB pharma unit hopes for sales in the $1bn region

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links